After liver surgery, two patients developed unexplainable prolonged prothrombin times (PT) that were not associated with bleeding tendency. The substitution of rabbit thromboplastin for either human or monkey thromboplastin in performing PT tests resulted in a normal clotting time. Tissue factor (TF) procoagulant activity assays and an immunoblotting analysis showed that these patients had developed IgG A-type immediate anticoagulants directed against both rabbit and bovineTF that did not crossreact with either human or monkey TF. In a chromogenic assay, the patient IgG caused a decrease in both the Km and the Vmax of the factor X activation by rabbit TF-factor Vlla complex. The lack of reactivity of the patient IgG with human TF presumably explained why there was no clinical bleeding. Both patients had been treated earlier with a ISSUE FACTOR (TF) is a transmembrane cell-surface T receptor and cofactor for coagulation factor VII/VIIa that mediates cellular initiation of the coagulation serine protease cascade.',' This is an essential step in the hemostatic response to vascular injury. The T F molecule contains three domains: a short cytoplasmic domain, a transmembrane region and an extracellular domain. The selective cellular expression of TF in vascular adventitia, organ capsules, epidermis, and mucosal epithelium has previously been shown.3 T F is anatomically sequestered from blood, being undetectable in endothelium and peripheral blood (PB) cells under normal circumstances.
reactive to either monkey or human TF, did not cause any bleeding tendency in these patients.
CASE REPORTS

Patient 1.
A 49-year-old Japanese man was admitted to our hospital in December I990 because of a huge metastatic liver tumor. He had previously undergone sigmoidectomy for cancer 5 years before. He had alcoholic liver disease with moderate liver dysfunction, but the coagulation tests were normal. On January 14, 199 1 he underwent extracorporeal liver surgery6 because the tumor was too large to be treated by conventional methods. Five grams of microfibrillar collagen hemostat was used for local hemostasis. His prothrombin time (PT) began to increase 1 week after the surgery and reached 20.0 seconds (normal range: 10.8 to 12.8 seconds) even though other coagulation tests had normalized. The PT continued to increase for about 3 months, and then gradually improved to a normal level by June 199 1. However, no bleeding problems were observed postoperatively. The recurrence of a metastatic tumor was found in the residual liver a year after the surgery. He subsequently underwent a resection of the tumor on January 7, 1992 during which time 1 g of microfibrillar collagen hemostat was used. The coagulation tests performed 2 weeks after the surgery again showed an isolated prolonged PT (1 9.4 seconds), but the postoperative course was uncomplicated. He was discharged on February 14, 1992 while the PT was still in a prolonged state. On July 25, 1992 he was readmitted to undergo a resection of a metastatic tumor in the right adrenal gland, and his PT was found to be normal. One week after the operation, he died of sepsis in the absence of a prolonged PT.
Patient 2. A 49-year-old woman was admitted to our hospital in March 1990 because of a huge metastatic liver tumor. She had undergone an abdominoperineal resection for rectal cancer 5 years before. On March 26, 1990 she underwent extracorporeal liver surgery during which time five grams of microfibrillar collagen hemostat were used as a topical hemostatic agent. Her postoperative recovery was unremarkable except that a slight increase of PT (13.3 seconds) was observed 3 weeks after surgery. In May 1991 she was readmitted because ofa recurrence ofthe liver tumor. The preoperative coagulation tests were normal. On May 20 she underwent an exploratory laparotomy in which the remnant liver was found to be loaded with multiple metastatic nodules. One gram of microfibrillar collagen hemostat was used during the operation. An isolated prolonged PT ( 17. I seconds) was observed I week after the surgery, continued for about 2 months, and then gradually improved to a normal level. No bleeding problems were observed postoperatively.
In both patients, antinuclear antibody, rheumatoid factor, serological tests for syphilis, and a Treponema pallidum hemagglutination test were negative. In addition, lupus anticoagulant, as determined by a diluted activated partial thromboplastin time (APTT) test,' was also found to be negative.
MATERIALS AND METHODS
Materials.
Protein A-Sepharose CLdB, concanavalin A-Sepharose, and diethyl aminoethyl (DEAE)-Sepharose CL-6B were obtained from Pharmacia-LKB (Uppsala, Sweden). Formyl-Cellulofine and protein A-Cellulofine were obtained from SeikagakuKogyo (Tokyo, Japan). The nitrocellulose membrane was from Toyo Roshi (Tokyo, Japan). The fluorogenic substrate Z-Pyr-GlyArg-4-methylcoumaryl-7-amide (Z-Pyr-Gly-Arg-MCA) was from Peptide Institute Inc (Osaka, Japan). Rabbit-brain cephalin was from Sigma Chemical Co (St Louis, MO). Nonimmunized rabbit IgG, rabbit antibodies against human 7-, p-and a-heavy chains and against K-and Might chains were obtained from Dakopatts (Glostrup, Denmark). Bio-beads SM-2 and horseradish peroxidase-conjugated goat antibody against rabbit IgG was from Bio-Rad Laboratories (Richmond, CA). Biotinylated sheep antibody against human Ig, biotinylated sheep F(ab'), fragments against mouse Ig and streptavidin-biotinylated horseradish peroxidase complex were from Amersham International plc (Amersham, UK). Thromboplastins of rabbit brain-lung, rabbit lung, monkey brain, and human placenta were obtained from Organon Teknika Co (Durham, NC), Mochida Pharmaceutical Co (Tokyo, Japan), Boehringer Mannheim (Mannheim, Germany), and Behringwerke AG (Marburg, Germany), respectively. Bovine brain acetone powder was provided by Eizai Co (Tokyo, Japan). Microfibrillar collagen hemostat was obtained from Alcon Inc (Humacao, Puerto Rico). Bicinchoninic acid (BCA) protein assay reagent was from Pierce Chemical Co (Rockford, IL). Triton X-100 was from Wako Pure Chemical Industries (Osaka, Japan). Tween 20 was obtained from Katayama Chemical Industries (Osaka, Japan). All other chemicals were the best analytical grade commercially available.
Proteins. TF was purified from bovine lung acetone powder according to the method of Broze et a18 with a slight modification. The purification procedure entailed 2% Triton X-100 extraction, concanavalin A-Sepharose chromatography, and bovine factor VIIcoupled formyl-Cellulofine affinity chromatography. Monospecific antisera against TF apoprotein was raised in a rabbit, from which IgG fraction was prepared by ammonium sulfate precipitation followed by protein A-Cellulofine column chromatography. The TF apoprotein wasrelipidated by incubation with rabbit brain cephalin in the presence of Bio-beads SM-2.9 The 2% Triton extract of thromboplastin of either rabbit lung, monkey brain, or human placenta was prepared as described previously.8 Factor VII' O and factor Xi' were purified from bovine plasma according to previously published methods. Bovine factor X was activated by the factor X activator from Russell's viper venom as described previously.'* Human factor VIIa was kindly provided by the Chemo-Sero Therapeutic Research Institute (Kumamoto, Japan). Monoclonal antibody (MoAb) against recombinant human TF was a generous gift from Dr K. Sueishi (Kyushu University, Fukuoka, Japan). The protein concentration of factor VIIa was determined by amino acid analysis while that of factor X was done by the extinction coefficient (E,,,,) of 1 2.4. 13 The active site of factor Xa was determined by titrati~n.'~ The protein concentration of TF was determined by a BCA assay15 using bovine serum albumin (BSA) as a standard.
Solubilization and enrichment of microjibrillar collagen hemostat. Four grams of microfibrillar collagen hemostat was suspended in 100 mL of 0.05 mol/L Tris-HC1, pH 7.4, 0.1 mol/L NaCl, 0.01% NaN, (Tris buffered saline [TBS]) containing 0.25% Triton X-100 and stirred overnight at 4°C. After centrifugation at l0,OOOg for 30 minutes at 4"C, the supernatant was lyophilized. The lyophilized powder was extracted with 200 mL of acetone to remove Triton X-100 and air-dried. The protein pellet was solubilized in 3 mL of TBS containing 0.1% Triton X-100 and dialyzed overnight against the same buffer at 4°C.
Blood was collected by venipuncture into 1/10 vol of 3.1 % sodium citrate. Platelet-poor plasma was prepared by centrifugation at 1,500g for 10 minutes at 4°C. Samples were immediately assayed or divided into aliquots and stored at -80°C until use.
Isolation oflgG. IgG was isolated from patient plasma or normal pooled plasma either by protein A-Sepharose column chromatography or by ammonium sulfate precipitation followed by DEAE-Sepharose CL-4B column chromatography.
Coagulation studies. PT, individual clotting factors, and other coagulation tests were assayed by standard techniques.I6
TF activity assays. After preincubating TF samples with an equal volume of IgG at 37"C, TF activity was assessed using either a clotting or a chromogenic assay. In a one-stage clotting assay, 200 pL ofthe mixture of TF sample and IgG was incubated with 100 pL of normal pooled plasma at 37°C for 2 minutes. Then 100 pL of 25-mmol/L CaC1, was added and clotting time was determined by a Behring Fibrintimer (Behringwerke AG). The percent residual activity was calculated from a standard curve prepared with serial dilutions of each TF sample.
In the chromogenic assay, 100 pL of the mixture of TF sample
and IgG was incubated with 40 p L of TBS containing 0.1 mg/mL BSA (TBSA), 10 pL of 0.1 mol/L CaCI, and 25 pL of human factor VIIa at 37°C for 5 minutes. Then 25 pL of bovine factor X was added and the incubation at 37°C was continued. After 5 minutes, the reaction was terminated by the addition of 500 pL of TBSA containing 10 mmol/L EDTA and 100 pmol/L Z-Pyr-Gly-Arg-MCA, the fluorogenic substrate of factor Xa. After incubation at 37°C for 10 minutes, 25 pL of2096 acetic acid was added to stop the reaction and the released 7-amino-4-methylcoumarin was measured fluorometrically with excitation at 380 nm and emission at 440 nm. The amount of factor Xa generated was calculated from a calibration curve prepared with serial dilutions of purified bovine factor Xa. Neutralization ofpatient IgG. Patient IgG was mixed with rabbit antibodies against specific Ig classes and chain types. The mixture was incubated for 18 hours at 4°C and then again for 1 hour at 37°C. After the precipitate was removed by centrifugation, the supernatant was examined for the inhibitory effects on the procoagulant activity of rabbit lung thromboplastin.
Immunoblotting analysis. Purified bovine-lung TF, the Triton X-100 extracts of thromboplastins and that of microfibrillar collagen hemostat were fractionated by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE)" and then were electrophoretically transferred to nitorcellulose membranes." The membranes were blocked with TBS containing 5% nonfat dry milk. Subsequently the membranes were incubated with patient IgG, normal human IgG, rabbit antibovine TF IgG, or murine MoAb against human recombinant TF overnight at room temperature. After extensive washing with TBS containing 0.05% Tween 20, the membranes were incubated in a second antibody (biotinylated sheep antibody against human IgG for patient IgG and normal human IgG, horseradish peroxidase-conjugated goat antibody against rabbit IgG for rabbit anti-TF IgG; and biotinylated sheep F(ab'), fragments against mouse Ig for MoAb for 2 hours. The membranes that had been incubated with either patient IgG, normal human IgG, or MoAb as the first antibody were further incu-
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RESULTS
In both patients, coagulation studies showed that factor VI1 activity was reduced postoperatively when PT was prolonged (patient 1: 13%; patient 2: 49%) whereas the activities of factors X, V, and I1 were normal. The mixing tests showed that the plasma from these patients were able to prolong the PT of normal plasma, indicating the presence of circulating inhibitors to the initial step in the extrinsic clotting cascade containing TF and factor VII.
Because neither patient showed bleeding tendency despite a markedly prolonged PT, we substituted the rabbit brain-lung thromboplastin routinely used in performing PT for the thromboplastins of varying species and tissues (Table  1) . Irrespective of tissue origin, the PT of both patients measured by either rabbit or bovine thromboplastin were significantly prolonged, which became more apparent with the use of more diluted thromboplastins (data not shown). In contrast, when either monkey or human thromboplastin was used, the PT became normalized. These data suggest that the inhibitors present in the plasma of these two patients were directed primarily not against factor VI1 but against rabbit and bovine T F with little or no reactivity to either human or monkey TF.
The IgG nature of the inhibitors was suggested by the disappearance of the inhibitory activity from the patient plasma after passing through a protein ASepharose column. The IgG fractions eluted from the column were analyzed for the effects on T F activity by both clotting and chromogenic assays. After incubating rabbit lung thromboplastin with the patient IgG, the residual T F activity was quantified in a one-stage clotting assay. The patient IgG inhibited T F activity in a dose-dependent manner (Fig 1A) with a maximal inhibition of more than 95%. The concentration of IgG producing half-maximal inhibition (ID5,) was 40 pg/mL for patient 1 and 160 pg/mL for patient 2. The inhibition was rapid and it was completed within 1 minute for patient 1 and within 4 minutes for patient 2 (Fig 1B) . In both patients, pretreatment ofthe patient Coagulation studies.
TF activity assays. IgG with rabbit antibody against either human y-heavy chains or Might chains completely abolished anti-TF activity of the patient IgG. However, pretreatment with nonimmunized rabbit IgG and that with rabbit antibody against either p-heavy chains, a-heavy chains or K-light chains had no effect. The inhibitory activity of the IgG from patient I was further evaluated using both purified bovine T F reconstituted with phospholipid and thromboplastins of different species. The patient IgG inhibited the procoagulant activities of both bovine lung T F and a saline extract of bovine lung acetone powder to the same extent. The maximal inhibition was 80% and the ID,, was 600 pg/mL. In contrast, the patient IgG did not inhibit the procoagulant activity of thromboplastin ofeither monkey brain nor human placenta even at a concentration of 8.0 mg/mL.
The effect of patient IgG on the factor X activation by TF-factor VIIa (TF-VIIa) complex was evaluated using rabFor personal use only. on November 16, 2017. by guest www.bloodjournal.org From bit lung thromboplastin. The IgG from both patients inhibited the factor X activation in a dose-dependent manner, but could not be completely blocked even at a concentration of 4.0 mg/mL IgG (residual activity: 50%). The ID,, was 550 pg/mL in both patients, which was much higher than that required in a clotting assay. However, the patient IgG had no effect on the amidolytic activity of factor Xa (data not shown). The kinetic parameters of factor X activation were determined by varying concentrations of factor X either in the presence or in the absence of IgG from patient 1 ( Table 2 ). When the concentration of factor VIIa was saturated (4.4 nmol/L), the patient IgG caused a decrease in both the Km and the Vmax, showing noncompetitive inhibition. Both parameters remained unchanged after incubation with normal human IgG (data not shown). The extent of the decrease of Vmax by the patient IgG was not affected by decreasing the concentration of factor VIIa to 0.2 nmol/ L, which may be explained by the fact that the antibodies are not directed against factor VIIa.
Immunoblotting analysis. To assess the binding of patient IgG to TF apoprotein, an immunoblotting analysis was performed. When the Triton X-100 extract of rabbit lung thromboplastin was fractionated by SDS-PAGE under reducing conditions (Fig 2A) , the IgG obtained from both patients just after surgery with a significantly prolonged PT showed several bands including a band of 42 Kd (lanes 1, 3,  and 4) . The 42-kD band was also seen in the Triton extract electrophoresed under nonreducing conditions (data not shown). However, the IgG obtained late after surgery when PT was normalized (lanes 2 and 5) as well as normal human IgG (lane 6 ) failed to stain this 42-Kd band. Both the patient IgG and normal human IgG did not stain any band with the Triton X-100 extract of thromboplastin of either human placenta (Fig 2B, lanes 1 through 6) or monkey brain (data not shown), although the MoAb against recombinant human TF identified a band of 43 Kd (lane 7). With the Triton X-100 extract of bovine lung acetone powder, the IgG prepared from the patient plasma with prolonged F T showed several bands including a band of molecular weight of 42 Kd (Fig 3A, lanes 1 and 2) , and a similar band was identified by rabbit antibovine TF IgG (lane 5). The binding of the Rabbit lung thromboplastin was incubated with TBSA alone or IgG from patient 1 (4.0 mg/mL) at 37°C for 10 minutes, followed by the addition of factor Vlla (0.2 or 4.4 nmol/L) and factor X (1 2.5 to 500 nmol/L). The rates of factor Xa formation was determined as described under Materials and Methods. The kinetic parameters of factor X activation were calculated by fitting the data to the double-reciprocal plotting of the rates of factor Xa formation versus the factor X concentrations. Data are expressed as means It SD for the number of experiments given by n. patient IgG to TF apoprotein was confirmed by the fact that the patient IgG stained a 42-Kd band with purified bovine TF (Fig 3B, lanes 1 and 2) . A band of the same molecular weight was seen by rabbit antibovine TF IgG (lane 5). However, normal human IgG did not stain any band with either the Triton extract of bovine lung acetone powder (Fig 3A,  lane 4) or purified bovine TF (Fig 3B, lane 4) . Thus, it appears that after surgery both patients transiently developed antibodies against TF apoprotein and several other proteins present in the Triton X-100 extract of bovine and rabbit thromboplastins.
The only material of animal origin that the patients had been exposed to during surgery was microfibrillar collagen hemostat. We hypothesized that microfibrillar collagen hemostat contains TF apoprotein by which the patients postoperatively developed inhibitors against bovine TF crossreactive to rabbit TF. The microfibrillar collagen hemostat was solubilized in Triton X-100, concentrated by lyophilization, and then reconstituted with phospholipid. However, this preparation did not show any TF activity either by clotting or chromogenic assays (data not shown). An immunoblotting analysis showed that the patient IgG stained a 42-Kd band with the Triton X-100 extract of microfibrillar collagen hemostat both under reducing (Fig 3C, lanes I and  2) and nonreducing (data not shown) conditions, although no band was stained by either normal human IgG (lane 4) or rabbit antibovine TF IgG (lane 5). To confirm the hypothesis, we examined whether the Triton extract of the collagen preparation was able to block the binding of the patient IgG to bovine TF. After incubation with the Triton extract ofthe collagen preparation, the IgG from patient 1 lost not only the reactivity to the Triton extract of the collagen preparation (Fig 3C, Lane 3 ) but also the reactivity to either the 42-Kd band in the Triton extract of bovine lung acetone powder (Fig 3A, lane 3) or purified bovine TF (Fig 3B, lane  3) . However, the incubation with 0.1% Triton X-100 produced no difference in the reactivity of the patient IgG (data not shown).
DISCUSSION
The present report is the first to describe the acquired antibody inhibitors to TF that developed postoperatively in two patients undergoing liver surgery. The patients showed isolated prolonged PT measured by rabbit and bovine thromboplastins, which were markedly enhanced by diluting the thromboplastins; however, neither of them were associated with bleeding tendency. The inhibitors immediately abolished the procoagulant activities of rabbit and bovine TF with no effect on those of monkey and human TF. The inhibitors appeared to be exclusively of the IgG X type and were completely neutralized by antibody against either y-heavy or A-light chains. Some inhibitors to factor VI11 and IX developed in hemophilia patients after replacement therapy also tend to show restricted heterogeneity, mostly of a single light-chain type and the same heavy-chain sub~lass.~.~ The characteristic of inhibition by the patient IgG was further evaluated by kinetic analysis. The patient IgG inhibited the factor X activation by TF-factor VIIa complex with decreasing both the Km and the Vmax. The extent of the decrease of Vmax was not affected by the con- centration of factor VIIa. Therefore, it is suggested that some mechanism other than that interfering with substrate assembly to the complex must exist in the rapid inhibition by the patient IgG. The MoAbs against human TF that are noncompetitive inhibitors as the patient IgG have been reported to inhibit preformed TF-factor VIIa complex by dissociating factor Vlla from the cell surface TF.I9 An immunoblotting analysis showed that the patient IgG was observed to bind to purified bovine TF apoprotein. Although the patient IgG stained several bands, including the band probably corresponding to TF in the Triton extracts of both rabbit thromboplastin and bovine acetone powder, no band was shown in the Triton extract of either monkey or human thromboplastin. The species specificity of the antibodies in both the inhibition of TF activity and the binding to TF apoprotein may reconcile the discrepancy between the presence of markedly prolonged PT and the absence of hemorrhagic problems during the clinical courses of both patients. Recently, regarding the amino acid sequence of bovine TF, 74.1% has been reported to be identical to rabbit TF, and 70.4% is identical to human TF. However, there is a highly variable sequence among these TF near the N-terminus of the extracellular domain.20 Therefore, the patient IgG may be associated with bovine and rabbit TF near this region and inhibit the interaction between TF and human factor Vlla.
Each of the two patients had undergone liver surgery twice for metastatic cancer originating from either the sigmoid colon or the rectum. The time of appearance of the antibodies against bovine and rabbit TF relative to the time of surgery suggests that the patients may have been exposed to antigen during surgery. In our hospital, microfibrillar collagen hemostat has been used as a topical hemostatic agent particularly in liver surgery, being applied to cover the raw surface of the liver, followed by saline imgation for removal. Microfibrillar collagen hemostat is prepared from bovine corium by washing extensively with ethanol in the presence of HCI, milled into a flour-like form, and sterilized at 120°C for 28 hours.21 It is conceivable that the bovine corium used to prepare the collagen preparation could be contaminated by epidermis where high levels of TF expression has been rep~rted.~ Although in the Triton extract of the collagen preparation we could neither detect TF activity nor identify the band corresponding to TF by immunoblotting with rabbit antibovine TF IgG, the patient IgG stained a 42-Kd band in the Triton extract electrophoresed under either reducing or nonreducing conditions. In addition, the Triton extract of the collagen preparation blocked the binding of the patient IgG to bovine TF. Therefore, we suggest that the patients were indeed immunized during surgery with the bovine TF present in microfibrillar collagen hemostat, which was probably denatured by the sterilization 30 -2 0 -procedure, and postoperatively developed inhibitory antibodies against both bovine and rabbit TF. The antibodies caused a biologic "false positive" in PT measured by rabbit thromboplastin. In the course of preparing this article. we have encountered four additional patients who developed anti-TF antibodies of the same specificity as that observed in the reported cases. All of them had previously undergone either liver or spleen surgery during which time a low dosage of microfibrillar hemostat ( I g) had been used. Therefore, anti-TF antibody should be considered when postoperative patients show an unexplainable prolongation of PT measured by either rabbit or bovine thromboplastin.
